Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | IDO1 | P14902 | 9/20 | 0.64 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455344 | 0.89 | IDO1 (0.78) | KDM4EMAPTIDO1ALDH1A1GAA | |
| SCHEMBL16904097 | 0.86 | MAPT (0.74) | KDM4EMAPTIDO1ALDH1A1GAA | |
| SCHEMBL5445907 | 0.86 | MAPT (0.75) | KDM4EMAPTNOX1ALDH1A1GAA | |
| SCHEMBL8956455 | 0.86 | MAPT (0.75) | KDM4EMAPTNOX1ALDH1A1GAA | |
| Thiourea SCHEMBL1991944 | 0.84 | MAPT (0.73) | KDM4EMAPTNOX1ALDH1A1GAA | |
| SCHEMBL6811504 | 0.81 | RAB9A (0.68) | KDM4EMAPTNOX1ALDH1A1GAA | |
| SCHEMBL1642748 | 0.80 | IDO1 (0.67) | KDM4EMAPTIDO1ALDH1A1GAA | |
| SCHEMBL455323 | 0.80 | GAA (0.74) | KDM4EMAPTIDO1ALDH1A1GAA | |
| SCHEMBL9036606 | 0.78 | IDO1 (1.00) | KDM4EMAPTIDO1ALDH1A1EPHX1 | |
| SCHEMBL455548 | 0.78 | IDO1 (1.00) | KDM4EMAPTIDO1NOX1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016111658-A1 | SYNTHESIS OF THIOSEMICARBAZONE DERIVATIVES COMPRISING SULPHONAMIDE GROUP WITH POTENTIAL ANTICONVULSANT ACTIVITY | IYIDOGAN AYSEGUL (TR) | 2016-07-14 | — | — | WO | claimed |
| CN-102786464-B | Phthiobuzonum derivative and its production and use | BEIJING UNION PHARMACEUTICAL FACTORY (CN) | 2016-05-11 | — | — | CN | claimed |
| CN-102786464-A | Ftibamzone derivative and preparation method and application thereof | BEIJING UNION PHARMACEUTICAL FACTORY | 2012-11-21 | — | — | CN | claimed |
| CN-1990470-B | Phthiobuzonum derivative, its manufacturing process, pharmaceutical combination and uses thereof | BEIJING XIEHE PHARMACEUTICAL FACTORY | 2011-04-20 | — | — | CN | claimed |
| CN-122010896-A | Bicyclol derivative, pharmaceutical composition thereof, preparation method and application thereof | 中国医学科学院药物研究所 | 2026-05-12 | — | — | CN | disclosed |
| CN-114634502-B | 3-Aryl substituted thiazolidine-4-ketone-2-methylene hydrazono methylene-1H-indole derivative and preparation method thereof | 复旦大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-116874496-A | Tricyclic compound and preparation method, pharmaceutical composition and application thereof | 东南大学 | 2023-10-13 | — | — | CN | disclosed |
| CN-114634502-A | 3-aryl substituted thiazolidine-4-ketone-2-ylidenehydrazonomethylene-1H-indole derivatives and preparation method thereof | 复旦大学 | 2022-06-17 | — | — | CN | disclosed |
| WO-2022086079-A1 | DERIVATIVE OF SEMICARBAZONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2022-04-28 | — | — | WO | disclosed |
| US-11123350-B2 | Metal delivery agents and therapeutic uses of the same | THE UNIVERSITY OF MELBOURNE (AU) | 2021-09-21 | — | — | US | disclosed |
| US-20190298734-A1 | Metal Delivery Agents and Therapeutic Uses of the Same | THE UNIVERSITY OF MELBOURNE (AU) | 2019-10-03 | — | — | US | disclosed |
| CN-106699655-B | N- methyl Lomefloxacin aldehyde contracting 4- arylamino thiourea derivatives and its preparation method and application | 郑州工业应用技术学院 | 2019-09-24 | — | — | CN | disclosed |
| CN-1990470-A | Phthiobuzonum derivative, its manufacturing process, pharmaceutical combination and uses thereof | BEIJING XIEHE PHARMACEUTICAL F (CN) | 2007-07-04 | — | — | CN | disclosed |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| CN-1780822-A | Use of derivatives of 2, 4-dihydro- 1,2,4 triazole-3-thione as inhibitors of the enzyme myeloperoxidase (MPO) | ASTRAZENECA AB (SE) | 2006-05-31 | — | — | CN | disclosed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
| US-4871737-A | 3-Amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0315433-A2 | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4826866-A | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123350-B2 | Metal delivery agents and therapeutic uses of the same | SOD1, SLC30A6, SLC30A5 | KDM4E 4230/4885MAPT 53/4885IDO1 2857/4885 |
| US-20190298734-A1 | Metal Delivery Agents and Therapeutic Uses of the Same | SOD1, SLC30A6, SLC30A5 | KDM4E 4230/4885MAPT 53/4885IDO1 2857/4885 |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | KDM4E 2540/4885MAPT 2326/4885IDO1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.